Table 2.
Multivariable logistic regression analyses of factors associated with MASLD
| Panel A | Panel B | Panel C | Panel D | Panel E | |
|---|---|---|---|---|---|
| aOR (95% CI) |
aOR (95% CI) |
aOR (95% CI) |
aaOR (95% CI) |
OR (95% CI) |
|
| Age |
0.98 (0.96–1.00)* |
0.98 (0.96–1.00)* |
0.98 (0.96–1.00) |
0.97 (0.95–0.99)** |
0.98 (0.96–1.00) |
| Female sex |
0.85 (0.54–1.35) |
0.90 (0.57–1.42) |
0.80 (0.51–1.25) |
1.00 (0.64–1.57) |
1.02 (0.65–1.61) |
| Obesity |
2.12 (1.26–3.58)** |
1.58 (0.92–2.71) |
2.84 (1.71–4.72)*** |
2.78 (1.67–4.61)*** |
3.02 (1.80–5.04)*** |
| Diabetes |
1.81 (0.96–3.43) |
2.19 (1.16–4.14)* |
2.14 (1.15-4.00)* |
1.80 (0.96–3.41) |
2.27 (1.22–4.23)** |
| Arterial Hypertension |
1.24 (0.77–2.01) |
1.41 (0.87–2.29) |
1.27 (0.78–2.04) |
1.36 (0.84–2.20) |
1.28 (0.79–2.08) |
| Previous CVEs |
0.62 (0.24–1.61) |
0.62 (0.24–1.57) |
0.71 (0.28–1.79) |
0.66 (0.26–1.68) |
0.70 (0.28–1.75) |
| Low Fib-4 |
1.11 (0.64–1.93) |
1.14 (0.66–1.99) |
0.99 (0.57–1.70) |
1.01 (0.60–1.74) |
1.07 (0.62–1.84) |
| HOMA-IR ≥ 2.88 |
6.33 (3.78–10.61)*** |
– | – | – | – |
| LAP ≥ 57.08 | – |
7.76 (4.38–13.75)*** |
– | – | – |
| VAI ≥ 1.64 | – | – |
4.51 (2.84–7.17)*** |
– | – |
| TyG Index ≥ 4.69 | – | – | – |
4.26 (2.64–6.88)*** |
– |
| TG/HDL-C ≥ 2.49 | – | – | – | – |
4.08 (2.52–6.59)*** |
Panel A shows model including HOMA-IR ≥ 2.88, Panel B shows model including LAP ≥ 57.08, Panel C shows model including VAI ≥ 1.64, Panel D shows model including TyG Index ≥ 4.69, Panel E shows model including TG/HDL-C ≥ 2.49
aOR Adjusted odds ratio, CI Confidence interval, CVEs Cardiovascular events, HDL-C High-density lipoprotein cholesterol, HOMA-IR Homeostatic model assessment for insulin resistance, LAP Lipid accumulation product, VAI Visceral adiposity index, TyG Index Triglyceride-glucose index, TG/HDL-C Triglycerides to HDL-cholesterol ratio
*p < 0.05; **p < 0.01; ***p < 0.001